HOME >> MEDICINE >> NEWS
Injectable drug, combined with counseling, shows promise in treating alcohol dependence

overing how best to provide treatment -- like adding a safe medication to counseling. A long-acting injectable, which eliminates the burden of daily pill taking, will open new doors for our patients and give hope to them and their families," adds Dr. Pettinati.

A total of 627 alcohol-dependent patients were randomly assigned to receive either an injection of long-acting naltrexone or a placebo injection; 624 ultimately received at least one injection. In addition to an injection, all participants received low-intensity counseling consisting of 12 sessions during the six-month study, in addition to study medication. Long-acting naltrexone was associated with a reduction in heavy drinking within the first month of treatment, and this response was maintained over the six-month treatment period. In addition, long-acting naltrexone was generally well tolerated and side effects were predominantly mild and decreased over time. (The three most common side effects reported were nausea, headache and fatigue.)

The study was one of the largest trials of a medication for alcohol dependence and was conducted at 24 sites nationwide, including public, private hospitals and Veterans Administration clinics and tertiary-care medical centers. Other study authors included researchers from the medical schools at the University of Connecticut, Yale University, and Harvard University, and from Alkermes Incorporated, a biotechnology company based in Cambridge, Mass., that manufactures the long-acting naltrexone formulation (Vivitrex) used in the study.


'"/>

Contact: Ed Federico
ed.federico@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
5-Apr-2005


Page: 1 2

Related medicine news :

1. Mistletoe is not an anti-cancer drug, say doctors
2. RAND study shows solitary drug, alcohol and cigarette use puts adolescents at higher risk
3. The Journal of Clinical Pharmacology looks at effects of smoking cessation drug, varenicline
4. Stubborn ulcerative colitis responds to arthritis drug, review finds
5. Brain power combined to form new $125M institute
6. New study demonstrates combined techniques to detect, monitor Alzheimers disease
7. TPV EU approval provides new HIV active drug to be combined with FUZEON
8. 1.7m to build worlds first SIMS instrument combined with infra-red spectroscopy
9. Antibody combined with cancer drug shows promise against breast tumors
10. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
11. Medication combined with behavior therapy works best for ADHD children, study finds

Post Your Comments:
(Date:11/28/2014)... Brosix is always making changes to its infrastructure architecture ... efficient, effective, and secure experience. Most recently, the company ... ability to setup local servers for each country or ... around the globe. , 2. The ability to setup ... require millions of users in one network. , 3. ...
(Date:11/28/2014)... Dr. Diane Walder, one of the South ... Dr. Bridgit Nolan to her practice as a cosmetic ... her dermatology residency at the University of Miami Miller ... Nolan to join her practice because of her ... only does Dr. Nolan strive to provide the utmost ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Mirena ... move forward in New Jersey’s Bergen County Superior ... consolidated litigation established there is quickly approaching 1,300, ... on November 18th shows 1,293 lawsuits now pending ... lawsuits that allege complications resulting from spontaneous migration ...
(Date:11/28/2014)... 28, 2014 Miami's Plastic Surgery of ... Practice founder Dr. Jeffrey Epstein is excited ... a groundbreaking WordPress platform, the site is uniquely designed ... Currently, up to 75% of all prospective rhinoplasty patients ... people are logging on with smartphones, tablets, and laptops, ...
(Date:11/28/2014)... 28, 2014 Secura Consultants, based ... insurance marketing organizations in the country focused on ... protection marketplace. Secura Consultants is proud to offer ... Financial Group, a leading global financial company. , ... With the ownership interest comes the need for ...
Breaking Medicine News(10 mins):Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
(Date:11/28/2014)... endedChange %  30 September 201430 September 2013Turnover 546,011 , 534,641 ... 384,242 , 339,113 , 13.3 Hospital ... , 49.5 Medical Insurance Administration Service Income , ... and Accessories Sales , 94,580 , 142,683 ... , 9,219 , (68.4) Impairment Loss on Fixed ...
(Date:11/26/2014)... Nov. 26, 2014  Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... investor conferences. On Tuesday, December 2, the ... Piper Jaffray Healthcare Conference.  D. Keith Grossman , ... on the company beginning at 11:30 a.m., Eastern Standard ...
(Date:11/26/2014)... , Nov. 26, 2014  Cohen, Placitella ... behalf of investors who purchased Nymox Pharmaceutical Corporation ... during the period from January 31, 2011 through ... whether Nymox and certain of its officers and ... in violation of Sections 10(b) and 20(a) of ...
Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3
Cached News: